Summary of adverse events
| AE summary, n (%) . | VCD (n = 57) . | VCDD (n = 64) . |
|---|---|---|
| Any AE | 47 (82.5) | 57 (89.1) |
| Grade ≥3 AE | 23 (40.4) | 32 (50.0) |
| Grade ≥4 AE | 4 (7.0) | 10 (15.6) |
| Therapy-related AE | 37 (64.9) | 47 (73.4) |
| Grade ≥3 TR-AE | 13 (22.8) | 21 (32.8) |
| Grade ≥4 TR-AE | 2 (3.5) | 8 (12.5) |
| Daratumumab-related AE | 34 (53.1) | |
| Grade ≥3 DR-AE | 14 (21.9) | |
| Grade ≥4 DR-AE | 6 (9.4) | |
| Drug-related AE leading to permanent discontinuation | 4 (7.0) | 2 (3.1) |
| Drug-related AE leading to dose interruption/delay | 16 (28.1) | 24 (37.5) |
| Any SAE | 14 (24.6) | 19 (29.7) |
| Fatal SAE | 0 (0.0) | 1 (1.6) |
| Therapy–related fatal SAE | 0 (0.0) | 1 (1.6) |
| AE summary, n (%) . | VCD (n = 57) . | VCDD (n = 64) . |
|---|---|---|
| Any AE | 47 (82.5) | 57 (89.1) |
| Grade ≥3 AE | 23 (40.4) | 32 (50.0) |
| Grade ≥4 AE | 4 (7.0) | 10 (15.6) |
| Therapy-related AE | 37 (64.9) | 47 (73.4) |
| Grade ≥3 TR-AE | 13 (22.8) | 21 (32.8) |
| Grade ≥4 TR-AE | 2 (3.5) | 8 (12.5) |
| Daratumumab-related AE | 34 (53.1) | |
| Grade ≥3 DR-AE | 14 (21.9) | |
| Grade ≥4 DR-AE | 6 (9.4) | |
| Drug-related AE leading to permanent discontinuation | 4 (7.0) | 2 (3.1) |
| Drug-related AE leading to dose interruption/delay | 16 (28.1) | 24 (37.5) |
| Any SAE | 14 (24.6) | 19 (29.7) |
| Fatal SAE | 0 (0.0) | 1 (1.6) |
| Therapy–related fatal SAE | 0 (0.0) | 1 (1.6) |
AE, adverse event; SAE, serious adverse event.